Requests · The University of Texas Medical Branch at Galveston
Southeast Texas Gene Therapy & Precision Medicine Center
Priority 1 · one of 3 items in the The University of Texas Medical Branch at Galveston's request for 2028-29 · The item begins on page 106 of the request
This is a request, not an appropriation.
What is asked
| 2028 | 2029 | Two years | |
|---|---|---|---|
| All funds | $5,000,000 | $5,000,000 | $10,000,000 |
| Of which general revenue and general revenue-dedicated | $5,000,000 | $5,000,000 | $10,000,000 |
| Positions (full-time equivalents) | 5.0 | 5.0 |
How it would be financed
| Method of financing, as the request prints it | 2028 | 2029 |
|---|---|---|
| 1 General Revenue Fund | $5,000,000 | $5,000,000 |
| Total, as the request prints it | $5,000,000 | $5,000,000 |
Where it would land
The strategies this item would add to, numbered as the request numbers them, beside what each is appropriated in the current budget (2026-27 Act). One column is an appropriation and the other a request made on top of a base request not shown here, so the two are not subtracted.
| Strategy | Asked 2028 | Asked 2029 | Positions | Appropriated 2026 | Appropriated 2027 |
|---|---|---|---|---|---|
| 05-04-01 Exceptional Item Request | $5,000,000 | $5,000,000 | 5.0 | No strategy matched in the current budget | |
A strategy is matched by its name. Where none is matched, the strategy may be new, or may be in the current budget under a different name.
After 2029
| The agency's estimate | 2030 | 2031 | 2032 | Three years |
|---|---|---|---|---|
| All funds | $5,000,000 | $5,000,000 | $5,000,000 | $15,000,000 |
In the agency's words: Expectation to continue this project at the full amount.
The agency's justification
UTMB’s Gene Therapy Program is dedicated to the patient’s health, from initial genetic counseling, to ensuring safe and effective use of the therapy, to post-treatment care. There have been 17 patients treated with gene therapies at UTMB, from places across Texas. UTMB looks to grow our clinical and research abilities, meeting the needs of the moment to continue and advance our service of the Texas patient population. This initiative would recruit and retain dedicated health care providers, genetic experts, and researchers, while upgrading our care infrastructure and equipment. UTMB’s approach is multi-disciplinary, with robust expertise (Genetics, Dermatology, Cardiology, ENT, Neurology, and Anesthesia), facilitating the safe use of innovative treatments. UTMB’s medical genetics team is small, with no individuals staffed for 100% allocation to gene therapy clinical work (current focus is around 10% of clinical time for providers). State funding would allow investment in specialized health care providers (physicians, nurses), with established operational support, to facilitate gene therapies, alongside recruitment for additional, needed roles, such as research. Additional funding is necessary to build a medical genetics research arm, to allow clinical trial ability at our institution. This will allow UTMB to test emerging gene therapies and perfect delivery methods. UTMB’s Sealy Diagnostic Center utilizes precision medicine to provide innovative and advanced diagnostic services. The Center performs genomic analysis to better select medications or adjust dose to prevent toxicity or failure of therapy. Pathologists also use AI-assisted technologies to diagnose critical health conditions, including cardiovascular disease, bleeding and clotting disorders, chronic conditions and prostate cancer.
102 of 159 Allowing UTMB to continue offering more effective and innovative treatment options, as more gene therapies and diagnostics become available for patients, will save lives.
External and internal factors
UTMB is among the few centers in Texas offering FDA-approved gene therapies and specialty genetic drugs, for conditions including Duchenne/Becker Muscular Dystrophy (Elevidys), Hemophilia A (Roctavian), Recessive Dystrophic Epidermolysis Bullosa (Zevaskyn), and Spinal Muscle Atrophy (Zolgensma).UTMB is also home to the Sealy Diagnostic Center, which develops innovative diagnostic services, such as personalized genomic analysis, to better select medications or adjust doses to prevent toxicity or failure of a therapy. As more gene therapies become available for patients, UTMB’s specially equipped clinical care teams will uniquely position the institution to deepen clinical offerings to the Texas population.
As marked in the request
- Has an information technology part: No
- Costs anticipated after the two budget years: Yes
- Involves contracts over $50,000: No